Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 3 studies | 19% ± 2% | |
GABAergic neuron | 3 studies | 37% ± 14% | |
astrocyte | 3 studies | 20% ± 4% | |
glutamatergic neuron | 3 studies | 41% ± 17% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 27% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3679.23 | 1445 / 1445 | 100% | 18.50 | 183 / 183 |
pancreas | 100% | 1593.21 | 328 / 328 | 100% | 22.55 | 178 / 178 |
prostate | 100% | 5625.03 | 245 / 245 | 100% | 39.35 | 502 / 502 |
thymus | 100% | 6415.18 | 653 / 653 | 100% | 48.18 | 605 / 605 |
skin | 100% | 2902.81 | 1809 / 1809 | 100% | 25.69 | 471 / 472 |
uterus | 100% | 4015.49 | 170 / 170 | 100% | 23.08 | 458 / 459 |
brain | 100% | 3612.55 | 2635 / 2642 | 100% | 40.81 | 704 / 705 |
adrenal gland | 100% | 3813.91 | 258 / 258 | 100% | 33.26 | 229 / 230 |
stomach | 100% | 2583.01 | 359 / 359 | 99% | 17.30 | 284 / 286 |
intestine | 100% | 3709.33 | 966 / 966 | 99% | 18.46 | 523 / 527 |
liver | 100% | 1553.56 | 226 / 226 | 99% | 13.74 | 402 / 406 |
ovary | 100% | 4037.69 | 180 / 180 | 99% | 17.24 | 425 / 430 |
breast | 100% | 2799.82 | 459 / 459 | 99% | 23.51 | 1104 / 1118 |
kidney | 100% | 2601.93 | 89 / 89 | 99% | 17.25 | 889 / 901 |
bladder | 100% | 4606.62 | 21 / 21 | 99% | 20.23 | 497 / 504 |
lung | 100% | 2728.55 | 576 / 578 | 99% | 19.17 | 1139 / 1155 |
adipose | 100% | 2385.70 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4149.96 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 28.60 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 35.29 | 29 / 29 |
spleen | 100% | 4830.05 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 23.96 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.20 | 1 / 1 |
muscle | 99% | 1738.77 | 795 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 2821.87 | 919 / 929 | 0% | 0 | 0 / 0 |
heart | 96% | 1487.67 | 825 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071108 | Biological process | protein K48-linked deubiquitination |
GO_0006897 | Biological process | endocytosis |
GO_0070536 | Biological process | protein K63-linked deubiquitination |
GO_0008277 | Biological process | regulation of G protein-coupled receptor signaling pathway |
GO_0010508 | Biological process | positive regulation of autophagy |
GO_0006508 | Biological process | proteolysis |
GO_0016579 | Biological process | protein deubiquitination |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005813 | Cellular component | centrosome |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0001664 | Molecular function | G protein-coupled receptor binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | USP20 |
Protein name | Ubiquitin carboxyl-terminal hydrolase 20 (EC 3.4.19.12) (Deubiquitinating enzyme 20) (Ubiquitin thioesterase 20) (Ubiquitin-specific-processing protease 20) (VHL-interacting deubiquitinating enzyme 2) (hVDU2) |
Synonyms | VDU2 LSFR3A KIAA1003 |
Description | FUNCTION: Deubiquitinating enzyme that plays a role in many cellular processes including autophagy, cellular antiviral response or membrane protein biogenesis . Attenuates TLR4-mediated NF-kappa-B signaling by cooperating with beta-arrestin-2/ARRB2 and inhibiting TRAF6 autoubiquitination . Promotes cellular antiviral responses by deconjugating 'Lys-33' and 'Lys-48'-linked ubiquitination of STING1 leading to its stabilization . Plays an essential role in autophagy induction by regulating the ULK1 stability through deubiquitination of ULK1 . Acts as a positive regulator for NF-kappa-B activation by TNF-alpha through deubiquitinating 'Lys-48'-linked polyubiquitination of SQSTM1, leading to its increased stability . Acts as a regulator of G-protein coupled receptor (GPCR) signaling by mediating the deubiquitination beta-2 adrenergic receptor (ADRB2). Plays a central role in ADRB2 recycling and resensitization after prolonged agonist stimulation by constitutively binding ADRB2, mediating deubiquitination of ADRB2 and inhibiting lysosomal trafficking of ADRB2. Upon dissociation, it is probably transferred to the translocated beta-arrestins, possibly leading to beta-arrestins deubiquitination and disengagement from ADRB2 . This suggests the existence of a dynamic exchange between the ADRB2 and beta-arrestins. Deubiquitinates DIO2, thereby regulating thyroid hormone regulation. Deubiquitinates HIF1A, leading to stabilize HIF1A and enhance HIF1A-mediated activity . Deubiquitinates MCL1, a pivotal member of the anti-apoptotic Bcl-2 protein family to regulate its stability . Within the endoplasmic reticulum, participates with USP33 in the rescue of post-translationally targeted membrane proteins that are inappropriately ubiquitinated by the cytosolic protein quality control in the cytosol . . |
Accessions | ENST00000315480.9 Q9Y2K6 ENST00000358355.5 ENST00000372429.8 |